Acura Pharmaceuticals Inc. (NASDAQ: ACUR) is getting crushed this morning after an FDA advisory panel recommended that the FDA not approve its new opioid painkiller Acurox. Its partner King Pharmaceuticals Inc. (NYSE: KG) is also down on the news. Average volume in Acura is only 130,000 shares and the 52-week trading range was $4.00 to $9.13.
Acura is down 37% at $3.70 on about 175,000 shares as of 9:27 AM EST. King was indicated lower but is now flat at $11.10 on very thin volume.
JON OGG
No comments:
Post a Comment